Brussels, 08/11/2001 (Agence Europe) - The European Commission has authorised, by centralised procedure, the Community marketing of a new medicine for the treatment of certain forms of leukaemia. As it is an orphan medicine, the product will benefit from ten year protection on the EU15 market. Already authorised and marketed in the United States and Switzerland since 26 June, Glivec has been developed by the Novartis laboratory, which is currently making new trials with a view to determining...